Home > News > Nanogen Earns Two Patents
April 17th, 2006
Abstract:
Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today that it has been issued two patents by the U.S. Patent and Trademark Office for inventions related to disease biomarkers. U.S. Patent No. 7,014,854, "Method for Retarding or Precluding Alzheimer's Dementia" claims use of immune system modulation to remove proteins associated with Alzheimer's disease (AD). An unrelated patent, U.S. Patent No. 7,015,004, relates to the isolation and use of a biomarker to diagnose metabolic syndrome.
Source:
snl.com
Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||